Nanotechnology and the Quest for the Ultimate Drug-Delivery System - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Nanotechnology and the Quest for the Ultimate Drug-Delivery System


Pharmaceutical Technology


So quo vadis (where are we going)? Based on where we are and what is being proposed as the future of nanotechnology, I believe we should revisit the initial impetus for the development of nanotechnology. Not the nanotechnology that complains about "thick fingers" but the nanotechnology that sees the extraordinary potential in the "Engines of Creation." We should aim for the nanotechnology that cures disease not by administering small, smart drug-delivery systems but by fixing molecular abnormalities permanently. We should shoot for the nanotechnology that uses "nanobots" in such a way that disease or disability cease to exist. I know this is a lofty goal, but I believe it is one we should pursue because throughout history, all new, radical technologies have brought about initial fear and trepidation, but eventually these fears were overcome.

Just how can we change the mindset of those controlling the direction of nanotechnology? We might take solice in a famous passage by the great physicist Max Planck: "A new scientific truth does not triumph by convincing its opponents and making them see the light, but rather because its opponents eventually die and a new generation grows up that is familiar with it." Perhaps a new generation of scientists who grew up with nanobots, nanoids, and nanites as part of their vocabulary, the books they read, the games they played, and the movies and TV shows they saw will not be afraid to explore the incredible possibility of fixing abnormalities in the molecular machinery of life using functional systems engineered at the molecular scale.

Melgardt M. de Villiers, PhD, is an associate professor at the Univ. of Wisconsin-Madison School of Pharmacy, 777 Highland Avenue, Madison, WI 53705-2222, tel. 608. 890.0732


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
29%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
13%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: Pharmaceutical Technology,
Click here